glp-1 medication side effects management strategies Eating Well on Your Journey: A Guide for Maximizing Results and Minimizing GLP-1 Medications Infographic | Medidex

After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025

Understanding how GLP-1 medications compare to older weight loss drugs like phentermine also helps frame the conversation

Zepbound, for example, is FDA-approved for adults with obesity or overweight with at least one weight-related condition, in addition to nutrition and activity changes

Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer